American Society of Hirudotherapy

Hirudotherapy for neonatal limb ischemia during ECMO support: A word of caution

Research article published in Journal of cardiac surgery (2021)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Clinical TrialsResch J et al. · Journal of cardiac surgery, 2021

Abstract

INTRODUCTION: Disordered coagulation, clot formation and distal limb ischemia are complications of extracorporeal membrane oxygenation (ECMO) with significant morbidity and mortality. Medicinal leech therapy (hirudotherapy) has been attempted in plastic and orthopedic surgeries to improve venous congestion and salvage ischemic flaps. To our knowledge this has not been reported in pediatric cardiac surgery or during ECMO support. We present a complex neonate whose ECMO course was complicated by distal limb ischemia for whom leech therapy was attempted. PATIENT AND INTERVENTION: A 2-week-old 2.7 kg infant required ECMO support secondary to perioperative multiorgan system dysfunction following repair of critical coarctation and ventricular septal defect. Despite systemic anticoagulation, his clinical course was complicated by arterial thrombus, vasopressor-induced vascular spasm and bilateral distal limb ischemia. Medicinal leech therapy was tried after initially failing conventional measures. RESULT: Following the third leech application, this patient developed significant hemorrhage from the web space adjacent to the left great toe. An estimated 450 ml of blood loss occurred and more than 300 ml of blood product transfusions were required. He ultimately progressed to irreversible systemic end organ dysfunction and comfort care was provided. CONCLUSION: The use of medicinal leech therapy in pediatric cardiac surgery may be considered to minimize the consequences of advanced limb ischemia and venous congestion. However, this should be used with caution while patients are systemically anticoagulated during ECMO support. A directed review is presented here to assist in determining optimal application and potential course of therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsCardiac Surgical ProceduresChildExtracorporeal Membrane OxygenationHumansInfantInfant, NewbornIschemiaLeechingMaleRetrospective Studies

Summary

Disordered coagulation, clot formation and distal limb ischemia are complications of extracorporeal membrane oxygenation (ECMO) with significant morbidity and mortality.

Why This Matters for Hirudotherapy

Contributes clinical evidence for the therapeutic application of leech therapy.

Citation

Hirudotherapy for neonatal limb ischemia during ECMO support: A word of caution.

Resch J et al. · Journal of cardiac surgery, 2021

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Hirudotherapy for neonatal limb ischemia during ECMO support: A word of caution | ASH